Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers

This study has been terminated.
(See termination reason in detailed description.)
Information provided by:
Pfizer Identifier:
First received: January 8, 2010
Last updated: August 3, 2010
Last verified: August 2010
The purpose of this study is to evaluate safety and tolerability after a single administration of PF-03382792 in healthy volunteers.; and to evaluate plasma drug levels and biological activity.

Condition Intervention Phase
Drug: PF-03382792 Cohort 1
Drug: PF-03382792 Cohort 2
Drug: PF-03382792
Drug: Food Effect cohort
Drug: CSF cohort
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Official Title: A Phase 1, First-Into-Human, Escalating Dose Trial To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-03382792 After Administration Of Single Oral Doses To Healthy Adult Subjects

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Safety endpoints include evaluation: adverse events, change from baseline in vital signs, triplicate ECG (Part A only), singlet ECG for Parts B and C. 8 hours of cardiac telemetry postdose (Part A only). [ Time Frame: For cohorts in Part A, up to 24 days; for Cohorts in Part B, up to 17; for Part C, up to 10 days ]
  • Additional Safety endpoints: clinical safety laboratory endpoints, plasma cortisol and ACTH, clinical examinations, slit lamp examination. [ Time Frame: For cohorts in Part A, up to 24 days; for Cohorts in Part B, up to 17; for Part C, up to 10 days ]
  • Pharmacokinetic endpoints: plasma concentration of PF 03382792 over time (eg, AUC, Cmax, Tmax, t1/2), plasma concentration of PF 03227077 over time (eg, AUC, Cmax, Tmax, t1/2). [ Time Frame: up to 72 hours post the final dose for each cohort ]

Secondary Outcome Measures:
  • Plasma aldosterone concentrations. [ Time Frame: For Part A and C; up to 24 hours post final dose ]
  • Change and percent change from baseline in average CSF sAPP fragment concentrations over all postdose collection time points up to 8 hours. • CSF sAPP fragment concentrations over time. • CSF concentration of PF 03382792 and PF [ Time Frame: Part C only, up to 8 hours post dose ]
  • 03227077 over time (eg, AUC, Cmax, Tmax). [ Time Frame: Part C only, up to 8 hours post dose ]

Enrollment: 10
Study Start Date: February 2010
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PART A: Ascending Cohorts
Single ascending dose cross-over. (0.05, 0.15, 0.5, 1.5, 5, 15 mg)
Drug: PF-03382792 Cohort 1
First cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
Drug: PF-03382792 Cohort 2
Second cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
Drug: PF-03382792
Optional cohort 3: Single oral ascending dose of PF-03382792, formulated in solution.
Experimental: PART B: Food effect
Food effect on PF-03382792 PK
Drug: Food Effect cohort
Single oral dose, cross-over to determine effect of food on PF-03382792 pharmacokinetics. Dose will be decided after reviewing data from the ascending dose portion.
Experimental: PART C: CSF Cohort
Optional CSF Cohort
Drug: CSF cohort
Single oral dose of PF-03382792 formulated in solution. Dose will be decided after reviewing data from the ascending dose portion.

Detailed Description:
Evaluate the safety, tolerability, plasma concentrations of PF-03382792 and other biological activity following a single dose of PF-03382792. Three ascending single doses of PF-03382792 were administered in this study (0.05 mg, 0.15mg and 0.5 mg). The decision to terminate the study was made on June 4, 2010 due to safety findings and limitations regarding the levels of the metabolite projected for doses above 0.5 mg.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • For all cohorts, healthy male and/or female subjects of nonchildbearing potential between the ages of 18 and 55 years, inclusive.

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
  • History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening.
  • Signs or symptoms of adrenal insufficiency.
  • Ocular lens (eye) abnormalities.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01045863

United States, Connecticut
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT01045863     History of Changes
Other Study ID Numbers: B1651001
Study First Received: January 8, 2010
Last Updated: August 3, 2010

Keywords provided by Pfizer:
volunteer processed this record on May 24, 2017